Declarations of interest Thorax: first published as 10.1136/thoraxjnl-2016-209333.476 on 15 November 2016. Downloaded from

KF Rabe reports financial for support for consultancy work P297 LUNG-FUNCTION PROFILE BEFORE AND AFTER THE from AstraZeneca, Chiesi, Novartis, MSD and GlaxoSmithKline, FIRST MODERATE TO SEVERE EXACERBATION DURING and grants from Altana, Novartis, AstraZeneca, MSD and THE WISDOM STUDY Nycomed. F Maltais reports financial support from Boehringer Ingelheim 10.1136/thoraxjnl-2016-209333.476 during the conduct of the study and, outside of the submitted work, financial support from Boehringer Ingelheim and GlaxoS- E Wouters, outside of the submitted work, reports personal fees mithKline for attendance at advisory boards, financial support from AstraZeneca, GlaxoSmithKline, Novartis, Takeda, Pfizer from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca and and Boehringer Ingelheim, and grants from AstraZeneca, GlaxoS- Novartis for speaking activities, and research support from Boeh- mithKline and Novartis. ringer Ingelheim, GlaxoSmithKline, AstraZeneca, Nycomed and H Magnussen received funding from Almirall, AstraZeneca, Novartis. Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novar- tis, Takeda and Roche to conduct clinical studies, and has spoken at meetings and is a member of advisory boards for these and P295 EFFICACY AND SAFETY OF TIOTROPIUM/OLODATEROL other companies. IN PATIENTS WITH COPD BY ATS CATEGORY R Rodriguez-Roisin reports personal fees from AstraZeneca, Boehringer Ingelheim, Mylan, Pearl Therapeutics, Takeda, Teva 10.1136/thoraxjnl-2016-209333.474 and Ferrer, and grants and personal fees from Menarini and Almirall. F Maltais reports financial support from Boehringer Ingelheim K Tetzlaff and S Bell are employees of Boehringer Ingelheim during the conduct of the study and, outside of the submitted Pharma GmbH & Co. KG. PMAC reports financial support in work, financial support from Boehringer Ingelheim and GlaxoS- the form of a grant from Boehringer Ingelheim to conduct the mithKline for attendance at advisory boards, financial support study and, outside of the submitted work, reports personal fees from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca and from GlaxoSmithKline, AstraZeneca, Takeda and Boehringer Novartis for speaking activities, and research support from Boeh- Ingelheim, and grants from GlaxoSmithKline and Takeda. ringer Ingelheim, GlaxoSmithKline, AstraZeneca, Nycomed and Novartis. E Pizzichini has nothing to disclose. L Grönke and F Voß are employees of Boehringer Ingelheim P298 TIOTROPIUM/OLODATEROL THERAPY PROVIDES Pharma GmbH & Co. KG. SYMPTOMATIC BENEFITS IRRESPECTIVE OF PRIOR E Derom, outside of the submitted work, reports financial MAINTENANCE TREATMENT: POST HOC ANALYSES OF support from Boehringer Ingelheim, Actelion, AstraZeneca and THE OTEMTO® STUDIES Cipla for consultancy work, financial support from Chiesi, Astra- Zeneca and CSL Behring for advisory board attendance, and 10.1136/thoraxjnl-2016-209333.477 research support from Boehringer Ingelheim and

GlaxoSmithKline. R Abrahams reports grants and personal fees from Boehringer http://thorax.bmj.com/ Ingelheim during the conduct of the study and, outside of this work, grants and personal fees from GlaxoSmithKline and grants P296 EFFECT OF TIOTROPIUM/OLODATEROL THERAPY ON from AstraZeneca and Pearl Therapeutics. COPD EXACERBATIONS IN THE TONADO® STUDIES GT Ferguson, during the conduct of the study, reports grants, personal fees and non-financial support from Boehringer Ingel- 10.1136/thoraxjnl-2016-209333.475 heim and, outside the submitted work, grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees

from GlaxoSmithKline, grants and personal fees from Novartis, on October 1, 2021 by guest. Protected copyright. E Derom, outside of the submitted work, reports financial sup- AstraZeneca, Pearl Therapeutics and Sunovion, and grants from port from Boehringer Ingelheim, Actelion, AstraZeneca and Cipla Forest. for consultancy work, financial support from Chiesi, AstraZeneca L Bjermer reports no conflicts of interest. and CSL Behring for advisory board attendance, and research L Grönke and F Voß are employees of Boehringer Ingelheim support from Boehringer Ingelheim and GlaxoSmithKline. Pharma GmbH & Co. KG. M Fležar has received personal fees from Boehringer Ingel- D Singh reports other financial activities from Boehringer heim and institutional financial support from Novartis. Ingelheim during the conduct of the study and, outside of the L Grönke and F Voß are employees of Boehringer Ingelheim submitted work, grants and personal fees from Almirall, AstraZe- Pharma GmbH & Co. KG. neca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, R Buhl reports financial support to his institution from Boeh- Johnson & Johnson, Merck, NAPP, Novartis, Pfizer, Takeda, ringer Ingelheim during the conduct of the study and, outside of Teva, Theravance and Verona, and personal fees from Genentech the submitted work, financial support from Boehringer Ingel- and SkyePharma. heim, AstraZeneca, Chiesi, Novartis, Teva, Roche and GlaxoS- mithKline for attendance at advisory boards and speaking activities, and research support to his institution from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Roche.

Thorax 2016;71(Suppl 3):A1–A288 A273